If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Victoza Side Effects Reported to FDA

The following Victoza reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.

The appearance of Victoza on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.

Intraocular Pressure Increased

This is a report of a 62-year-old male patient (weight: NA) from US, suffering from the following symptoms/conditions: type 2 diabetes mellitus, who was treated with Victoza (dosage: 1.8 Mg, Qd, start time: Nov 26, 2012), combined with:

Metformin

Lantus

and developed a serious reaction and side effect(s). The consumer presented with:

Intraocular Pressure Increased

which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Victoza treatment in male patients, resulting in intraocular pressure increased side effect.

This report suggests a potential Victoza Nausea, Weight Decreased, Headache, Pyrexia, Rash Pruritic, Heart Rate Increased side effect(s) that can have serious consequences. A 64-year-old female patient (weight: NA) from US was diagnosed with the following symptoms/conditions: diabetes mellitus management and used Victoza (dosage: Given Into/under The Skin) starting Oct 10, 2013. Soon after starting Victoza the patient began experiencing various side effects, including:

Nausea

Weight Decreased

Headache

Pyrexia

Rash Pruritic

Heart Rate Increased

Drugs used concurrently: NA.The patient was hospitalized. Although Victoza demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as nausea, may still occur.

Urinary Retention, Cough, Respiratory Tract Congestion

This Urinary Retention, Cough, Respiratory Tract Congestion problem was reported by a consumer or non-health professional from US. A 55-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: weight control,blood glucose increased. On NS this consumer started treatment with Victoza (dosage: NA). The following drugs were being taken at the same time: NA. When commencing Victoza, the patient experienced the following unwanted symptoms/side effects:

Urinary Retention

Cough

Respiratory Tract Congestion

Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as urinary retention, may become evident only after a product is in use by the general population.

Pancreatic Carcinoma

This is a report of a 55-year-old female patient (weight: NA) from ES. The patient developed the following symptoms/conditions: type 2 diabetes mellitus and was treated with Victoza (dosage: Unk) starting 201211. Concurrently used drugs: NA.Soon after that, the consumer experienced the following side effects:

Pancreatic Carcinoma

This opens a possibility that Victoza treatment could cause the above reactions, including pancreatic carcinoma, and some female subjects may be more susceptible.

Coronary Artery Occlusion, Vomiting

A 62-year-old male patient (weight: NA) from US with the following symptoms/conditions: type 2 diabetes mellitus started Victoza treatment (dosage: 0.6 Mg Qd) on 201310. Soon after starting Victoza treatment, the subject experienced various side effects, including:

Coronary Artery Occlusion

Vomiting

Concurrently used drugs: NA.The patient was hospitalized. This finding indicates that some male patients could be more vulnerable to Victoza.

Pancreatic Carcinoma, Metastases To Liver

A 62-year-old female patient from US (weight: NA) experienced symptoms, such as: NA and was treated with Victoza(dosage: NA). The treatment was initiated on 201302. After that a consumer reported the following side effect(s):

Pancreatic Carcinoma

Metastases To Liver

Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Victoza efficacy: NA.

Pancreatitis

In this report, Victoza was administered for the following condition: type 2 diabetes mellitus.A 55-year-old male consumer from US (weight: NA) started Victoza treatment (dosage: NA) on Oct 30, 2013.Sometime after starting the treatment, the patient complained of the following side effect(s):

Pancreatitis

A possible interaction with other drugs could have contributed to this reaction: NA.The patient was hospitalized.Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Victoza treatment could be related to the listed above side effect(s).

Pancreatic Carcinoma, Bile Duct Cancer

This is a report of the following Victoza side effect(s):

Pancreatic Carcinoma

Bile Duct Cancer

A 79-year-old male patient from US (weight: NA) presented with the following condition: diabetes mellitus and received a treatment with Victoza (dosage: NA) starting: Dec 12, 2012.The following concurrently used drugs could have generated interactions:

Bystolic

Lipitor

Glipizide

Imdur

Losartan

Asa

Ranitidine

Metformin

The patient was hospitalized.This report suggests that a Victoza treatment could be associated with the listed above side effect(s).

Cerebrovascular Accident, Tachyarrhythmia

This Victoza report was submitted by a 60-year-old male consumer from FR (weight: NA). The patient was diagnosed with: NA and Victoza was administered (dosage: 1.2 Mg, Qd) starting: NS. The consumer developed a set of symptoms:

Cerebrovascular Accident

Tachyarrhythmia

Other drugs used simultaneously:

Metformine

Those unexpected symptoms could be linked to a Victoza treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Pancreatitis

This is a report of a possible correlation between Victoza use and the following symptoms/side effect(s):

Pancreatitis

which could contribute to an assessment of Victoza risk profile.A 74-year-old male consumer from US (weight: NA) was suffering from type 2 diabetes mellitus and was treated with Victoza (dosage: 0.6 Mg, Qd) starting Jan 09, 2014.Other concurrent medications: NA.

Pancreatic Carcinoma Metastatic

A 71-year-old male patient from US (weight: NA) presented with the following symptoms: type 2 diabetes mellitus and after a treatment with Victoza (dosage: 1.2 Mg, Qd) experienced the following side effect(s):

Pancreatic Carcinoma Metastatic

The treatment was started on 2003. Victoza was used in combination with the following drugs:

Janumet

Baby Aspirin (Unk)

Baby Aspirin

Vitamin D /00107901/ (Unk)

Vitamin E (Unk)

Fish Oil Omega 3 (Unk)

The patient was hospitalized.This report could alert potential Victoza consumers.

In this report, a 65-year-old male patient from CH (weight: NA) was affected by a possible Victoza side effect.The patient was diagnosed with type 2 diabetes mellitus. After a treatment with Victoza (dosage: 1.8 Mg, Qd, start date: NS), the patient experienced the following side effect(s):

Acute Coronary Syndrome

Pancreatic Carcinoma Metastatic

Hyperglycaemia

The following simultaneously used drugs could have led to this reaction:

Tresiba (80 U, Qd)

Novorapid (Unk)

Valsartan (0.5 Tab, Qd (320mg/25mg))

Actos (30 Mg, Qd)

Pantozol /01263204/ (40 Mg, Bid)

Pantozol /01263204/

Thioctacid /00213801/ (600 Mg, Qd)

Humalog (Unk (according To Outline))

The patient was hospitalized.The findings here stress that side effects should be taken into consideration when evaluating a Victoza treatment.

Pancreatic Carcinoma Metastatic

This is a report of a 65-year-old male patient from US (weight: NA), who used Victoza (dosage: 1.8 Mg, Qd) for a treatment of type 2 diabetes mellitus. After starting a treatment on Aug 29, 2012, the patient experienced the following side effect(s):

Pancreatic Carcinoma Metastatic

The following drugs could possibly have interacted with the Victoza treatment

Iron (27 Mg, Unk)

Vitamin B12 /00056201/ (1000 ?g, Qd)

Aspirin E.c (81 Mg, Qd)

Vitamin D3 (2000 Iu, Bid)

Fish Oil (120 Mg-180 Mg, Qd)

Glucosamine Chondroitin /01430901/ (600 Mg-750 Mg, Qd)

Nitrostat (0.4 Mg, Prn)

Amlodipine Besylate (2.5 Mg, Qd)

Taken together, these observations suggest that a Victoza treatment could be related to side effect(s), such as Pancreatic Carcinoma Metastatic.

Stent Placement

This stent placement side effect was reported by a consumer or non-health professional from US. A 59-year-old female patient (weight:NA) experienced the following symptoms/conditions: type 2 diabetes mellitus. The patient was prescribed Victoza (dosage: 1.8 Mg Daily), which was started on 2008. Concurrently used drugs: NA. When starting to take Victoza the consumer reported the following symptoms:

Stent Placement

These side effects may potentially be related to Victoza.

Stent Placement

This is a Victoza side effect report of a 59-year-old female patient (weight:NA) from US, suffering from the following symptoms/conditions: type 2 diabetes mellitus, who was treated with Victoza (dosage:1.8 Mg Daily, start time: 2008), combined with: NA., and developed a serious reaction and a stent placement side effect. The patient presented with:

Stent Placement

which developed after the beginning of treatment. This side effect report can indicate a possible existence of increased vulnerability to Victoza treatment in female patients suffering from type 2 diabetes mellitus, resulting in stent placement.

Cholangiocarcinoma, Metastases To Liver

This report suggests a potential Victozacholangiocarcinoma side effect(s) that can have serious consequences. A 51-year-old female patient from GB (weight:NA) was diagnosed with the following health condition(s): NA and used Victoza (dosage: 1.2 Mg) starting 2007. Soon after starting Victoza the patient began experiencing various side effects, including:

Cholangiocarcinoma

Metastases To Liver

Drugs used concurrently:

Sitagliptin (100 Mg)

Buscopan (Unk)

Chlorpromazine (75 Mg)

Humulin I (Unk)

Omeprazole (20 Mg)

Pregabalin (75 Mg)

Although Victoza demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as cholangiocarcinoma, may still occur.

Diarrhoea, Malaise

This diarrhoea problem was reported by a pharmacist from GB. A 67-year-old male patient (weight: NA) was diagnosed with the following medical condition(s): NA.On Dec 06, 2013 a consumer started treatment with Victoza (dosage: Unk). The following drugs/medications were being taken at the same time:

Amitriptyline (Unk)

Aspirin (Unk)

Atorvastatin (Unk)

Ezetrol (Unk)

Gliclazide (Unk)

Lansoprazole (Unk)

Lercanidipine (Unk)

Metformin (Unk)

When commencing Victoza, the patient experienced the following unwanted symptoms /side effects:

Diarrhoea

Malaise

Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as diarrhoea, may become evident only after a product is in use by the general population.

Blood Triglycerides Increased, Pancreatitis Acute

This is a Victoza side effect report of a 50-year-old female patient (weight: NA) from FR. The patient developed the following symptoms/conditions: type 2 diabetes mellitus,dyslipidaemia and was treated with Victoza (dosage: 1.80 Mg, Qd) starting 2008. Concurrently used drugs:

Omacor (3 Df, Qd)

Metformin (1700 Mg, Qd)

Lasilix /00032601/ (40 Mg, Qd)

Triatec /00116401/ (5 Mg, Qd)

Kaleorid (1000 Mg, Qd)

Kardegic (75 Mg, Qd)

Cardensiel (2.50 Mg, Qd)

Nureflex (1200 Mg, Qd)

Soon after that, the consumer experienced the following of symptoms:

Blood Triglycerides Increased

Pancreatitis Acute

The patient was hospitalized. This opens a possibility that Victoza could cause blood triglycerides increased and that some female patients may be more susceptible.

Pancreatic Carcinoma

A 63-year-old male patient (weight: NA) from US with the following symptoms: type 2 diabetes mellitus started Victoza treatment (dosage: 18mg/3ml Once Daily) on 2011. Soon after starting Victoza treatment, the consumer experienced several side effects, including:

Pancreatic Carcinoma

. Concurrently used drugs: NA.The patient was hospitalized. This finding indicates that some patients can be more vulnerable to developing Victoza side effects, such as pancreatic carcinoma.

Cerebrovascular Accident

This cerebrovascular accident side effect was reported by a health professional from US. A 72-year-old female patient (weight:NA) experienced the following symptoms/conditions: type 2 diabetes mellitus.The patient was prescribed Victoza (dosage: 1.8 Mg, Qd), which was started on Jul 11, 2013. Concurrently used drugs: NA..When starting to take Victoza the consumer reported symptoms, such as:

Cerebrovascular Accident

These side effects may potentially be related to Victoza. The patient was hospitalized.

Pancreatic Carcinoma Metastatic, Off Label Use

This is a report of a 62-year-old male patient (weight: NA) from US, suffering from the following symptoms/conditions: diabetes mellitus,obesity, who was treated with Victoza (dosage: 1.8 Mg, Qd, start time: 201203), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:

Pancreatic Carcinoma Metastatic

Off Label Use

which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Victoza treatment in male patients, resulting in pancreatic carcinoma metastatic side effect. The patient was hospitalized.

International Normalised Ratio Decreased, Off Label Use

This report suggests a potential Victoza Injection International Normalised Ratio Decreased, Off Label Use side effect(s) that can have serious consequences. A 49-year-old male patient (weight: NA) from GB was diagnosed with the following symptoms/conditions: diabetes mellitus,weight control and used Victoza Injection (dosage: 0.6 Mg, Qd) starting Jul 07, 2011. Soon after starting Victoza Injection the patient began experiencing various side effects, including:

International Normalised Ratio Decreased

Off Label Use

Drugs used concurrently: NA. Although Victoza Injection demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as international normalised ratio decreased, may still occur.

Hyperamylasaemia, Hyperlipasaemia, Abdominal Pain

This Hyperamylasaemia, Hyperlipasaemia, Abdominal Pain problem was reported by a health professional from FR. A 66-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: type 2 diabetes mellitus. On 2013 this consumer started treatment with Victoza (dosage: NA). The following drugs were being taken at the same time: NA. When commencing Victoza, the patient experienced the following unwanted symptoms/side effects:

Hyperamylasaemia

Hyperlipasaemia

Abdominal Pain

Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as hyperamylasaemia, may become evident only after a product is in use by the general population.

Hyperamylasaemia, Hyperlipasaemia

This is a report of a 57-year-old male patient (weight: NA) from FR. The patient developed the following symptoms/conditions: type 2 diabetes mellitus and was treated with Victoza (dosage: 1.8 Mg, Qd) starting Mar 06, 2012. Concurrently used drugs:

Novonorm

Metformine (1000 Mg)

Inegy (10/20)

Allopurinol

Coversyl /00790702/

Temerit

Kardegic

Soon after that, the consumer experienced the following side effects:

Hyperamylasaemia

Hyperlipasaemia

This opens a possibility that Victoza treatment could cause the above reactions, including hyperamylasaemia, and some male subjects may be more susceptible.

Adenocarcinoma Pancreas

A 72-year-old female patient (weight: NA) from US with the following symptoms/conditions: type 2 diabetes mellitus started Victoza treatment (dosage: Unk) on 200701. Soon after starting Victoza treatment, the subject experienced various side effects, including:

Adenocarcinoma Pancreas

Concurrently used drugs:

Byetta (Unk)

Januvia (Unk)

Janumet (Unk)

Bydureon (Unk)

The patient was hospitalized. This finding indicates that some female patients could be more vulnerable to Victoza.

Top 10 Victoza Side Effects for Men

Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

You can use them to remind you of details that may alert your health care professional(s) to a problem

You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

Log Form

You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

Medicine Name and Dosage:

Side Effects

Scale

Date & Time

Other Medicine(s) or Treatment(s)

Scale: 1 = very mild to 10 = very bad

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Victoza Reviews

Notice - The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Viewing and using of this information is subject to accepting Terms Of Use. PatientsVille.com
does not provide medical advice, diagnosis or treatment. The information regarding adverse reports, reviews and polls contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be
used to estimate the incidence of side effects, adverse drug reactions or for establishing or changing of patient treatments. Thank you for visiting Patientsville.com!